
Opinion|Videos|July 3, 2024
Gene Therapy for Treatment of Duchenne Muscular Dystrophy
Author(s)Emma Ciafaloni, MD
Focusing on gene therapy and exon skipping medications, an expert on Duchenne muscular dystrophy discusses current and emerging treatment options.
Advertisement
Episodes in this series

Video content above is prompted by the following questions:
- Provide an overview of delandistrogene moxeparvovec, micro-dystrophin gene therapy, that received accelerated approval for Duchenne muscular dystrophy (DMD) in 2023.
- Discuss ongoing studies for fordadistrogene movaparvovec gene therapy and other exon skipping therapies.
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Repositioning GLP-1 Drugs for Neurologic Disease: Evidence, Advances, and Outlook
2
Remyelinating Agent PIPE-307 Falls Short in Phase 2 Trial of Relapsing Multiple Sclerosis
3
What’s All the Buzz? Trending Topics and Phrases of Neurology in 2025
4
Brain-Penetrant Molecule GT-02287 Demonstrates Reversal of Glucosylsphinogosine in Parkinson Disease
5























